1,561 results match your criteria Clinical Hematology[Journal]


Compound heterozygous mutations Glu502Lys and Met527Thr of the FXII gene in a patient with factor XII deficiency.

Hematology 2019 Dec;24(1):420-425

a Department of Clinical Laboratory , The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , People's Republic of China.

Objective: To study the gene mutation of human coagulation factor XII (FXII) in a Chinese family with FXII deficiency and it will help us to understand the pathogenesis of this type of disease.

Clinical Presentation: The proband was a 50-year-old male who had a fracture of the right humerus. The routine presurgical coagulation test showed a significant prolonged activated partial thromboplastin time (APTT) at 59. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1598679DOI Listing
December 2019

Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: a retrospective study.

Hematology 2019 Dec;24(1):413-419

a Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma , Peking University Cancer Hospital & Institute , Beijing , People's Republic of China.

Objectives: To analyze the clinical characteristics and prognosis of primary extranodal classical Hodgkin lymphoma (PE-cHL).

Methods: Clinical features and outcomes of 22 PE-cHL patients who received initial chemotherapy January 2008 to January 2018 were analyzed retrospectively, and compared with 274 primary nodal Hodgkin lymphoma (PN-cHL) patients treated in the same period.

Results: With a median follow-up period of 42 months, compared with 274 PN-cHL patients, no significant difference of overall response rate (ORR) or complete remission (CR) rate was found, but the PE-cHL patients showed a higher recurrence rate (36. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1598678DOI Listing
December 2019
1 Read
1.189 Impact Factor

Abnormalities of quantities and functions of CD56bright natural killer cells in non-severe aplastic Anemia.

Hematology 2019 Dec;24(1):405-412

Objectives: The mechanism of non-severe aplastic anemia (NSAA) is not clear. It may be different from severe aplastic anemia (SAA). CD56bright NK cells (regulatory NK cells) is a subgroup of NK cells that produce immunoregulatory cytokines and express high-affinity IL-2 receptor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1590963DOI Listing
December 2019
2 Reads
1.189 Impact Factor

Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis.

Hematology 2019 Dec;24(1):392-398

a Department of Hematology , Peking Union Medical College Hospital , Beijing , People's Republic of China.

Purpose: To investigate the role of soluble programmed cell death ligand 1 (sPD-L1) protein in plasma of patients with Peripheral T-cell lymphoma (PTCL).

Methods: In total, 80 patients with newly diagnosed PTCL and 75 healthy controls were enrolled. Levels of sPD-L1 were measured by ELISA at diagnosis and after 3-8 courses of chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1590965DOI Listing
December 2019
1 Read

Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with thalidomide and VAD regimens.

Hematology 2019 Dec;24(1):387-391

a Department of Hematology , Second Affiliated Hospital, Xi'an Jiaotong University , Xi'an , People's Republic of China.

Objective: Frequent loss of expression of platelet factor 4 (PF4) in multiple myeloma (MM) was revealed in several previous researches. The predictive analysis of serum PF4 level in newly diagnosed MM has not been well elucidated. This study is to assess if serum PF4 could be a prognostic factor in predicting treatment response and survival of MM treated with thalidomide and VAD regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1592826DOI Listing
December 2019

Etiology and clinico-hematological profile of pancytopenia: experience of a Mexican Tertiary Care Center and review of the literature.

Hematology 2019 Dec;24(1):399-404

a Department of Haematology , Hospital Civil de Guadalajara "Fray Antonio Alcalde", University of Guadalajara , Guadalajara , Mexico.

Background: Pancytopenia is a frequent entity in clinical practice as a feature of a myriad of conditions, ranging from benign to malignant diseases. Since the cause of pancytopenia depends on environmental factors, it is important to know the common etiologies of pancytopenia, however, few studies address this.

Objectives: To identify the etiology of pancytopenia in our population and compare them with what is reported elsewhere. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1590961DOI Listing
December 2019
1 Read

Intrathecal dose intensification by CNS status at diagnosis in the treatment of children with acute lymphoblastic leukemia.

Hematology 2019 Dec;24(1):369-377

b Princess Noorah Oncology Center , King Saud Bin Abdulaziz University for Health Sceinces and King Abdulaziz Medical City, Ministry of National Guard Health Affairs , Jeddah , Saudi Arabia.

Objectives: Acute lymphoblastic leukemia (ALL) with CNS2 status predicts inferior outcome and a high rate of CNS relapse, similar to overt CNS leukemia (CNS3). The purpose of this study was to determine if intrathecal (IT) dose intensification during induction would improve outcomes and reduce CNS relapse for CNS2 disease.

Methods: From January 2001 to December 2014, children (1-14 years) with newly diagnosed ALL were treated at the Princess Noorah Oncology Centre (PNOC) following modifications of the Children's Oncology Group (COG) protocols. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1590962DOI Listing
December 2019
1 Read
1.189 Impact Factor

Efficacy of levofloxacin as an antibacterial prophylaxis for acute leukemia patients receiving intensive chemotherapy: a systematic review and meta-analysis.

Hematology 2019 Dec;24(1):362-368

b Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital , Mahidol University , Bangkok , Thailand.

Objectives: The incidence of febrile neutropenia (FN) in acute leukemia patients following induction or consolidation chemotherapy is high. Several clinical practice guidelines recommend the use of a fluoroquinolone prophylaxis to prevent bacterial infection in patients being prone to prolonged profound neutropenia.

Methods: This systematic review and meta-analysis aimed to investigate the efficacy and complications of levofloxacin as a prophylaxis for FN patients following chemotherapy for acute leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1589706DOI Listing
December 2019
1 Read
1.189 Impact Factor

Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.

Hematology 2019 Dec;24(1):355-361

a Department of Hematology and Hematopoietic Stem Cell Transplantation , Yamanashi Prefectural Central Hospital , Kofu , Japan.

Objectives: To explore real-world prognoses for tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) patients and the associated reasons for TKI discontinuation.

Methods: We investigated, using the medical records of 85 consecutive CML patients who received TKIs between December 2001 and August 2016 at our hospital, reasons for discontinuation, duration of TKI treatment before discontinuation, molecular response (MR) status at TKI discontinuation, treatment-free remission (TFR) duration, and overall survival after TKI discontinuation.

Results: TKI therapy was discontinued in 21 patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1590964DOI Listing
December 2019
1 Read

Clinical variability and molecular characterization of Hbs/Gγ (Aγδβ)0-thal and Hbs/HPFH in Indian sickle cell disease patients: AIIMS experience.

Hematology 2019 Dec;24(1):349-352

a Department of Hematology , All India Institute of Medical Sciences , New Delhi , India.

Introduction: In sickle cell disease (SCD) patients, among the predictors of survival, HbF levels play a significant role in lowering the morbidity and mortality. Coinheritance of δβ thalassemia and hereditary persistence of fetal hemoglobin (HPFH) may contribute to variable HbF levels in SCD patients, thus influencing their clinicopathological profile. Such cases are sparsely documented in the literature and thus, we screened the presence of δβ thalassemia and HPFH in 126 cases of SCD with high HbF. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/16078454.2019.1
Publisher Site
http://dx.doi.org/10.1080/16078454.2019.1579985DOI Listing
December 2019
4 Reads
1.189 Impact Factor

Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.

Hematology 2019 Dec;24(1):337-348

n Ospedale dell'Angelo , Mestre-Venezia , Italy.

Objectives: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10 Methods: Study population was from ALL study groups in Europe managed in national study protocols 2000-2014. MRD was measured by polymerase chain reaction or flow cytometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1567654DOI Listing
December 2019
11 Reads

GDF11 is increased in patients with aplastic anemia.

Hematology 2019 Dec;24(1):331-336

a Department of Hematology, General Hospital , Tianjin Medical University , Tianjin , People's Republic of China.

Object: To explore the critical role of growth differentiation factor 11 (GDF11) in the pathobiology of aplastic anemia (AA).

Methods: We have examined the serum GDF11 levels for 79 AA patients and 30 healthy controls. A total of 79 AA patients, which included 29 new diagnosed (untreated) cases, 14 cases with no response, 21 partial remission (PR) cases and 15 complete remission (CR) cases after immunosuppressive therapy (IST). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/16078454.2019.1
Publisher Site
http://dx.doi.org/10.1080/16078454.2019.1574386DOI Listing
December 2019
10 Reads

Correlation between RBC changes and coagulation parameters in high altitude population.

Hematology 2019 Dec;24(1):325-330

a Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College , Chengdu , People's Republic of China.

Objective: To explore the correlations between RBCs indexes and the basic coagulation parameters, and provide data for further studies on high altitude-induced thrombotic disease.

Methods: A total of eligible 433 volunteers were divided into different groups according to HGB concentration and HCT, respectively. PT, APTT, TT and Fbg were measured by clotting assays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1568658DOI Listing
December 2019
3 Reads

Long non-coding RNAs MALAT1, MIAT and ANRIL gene expression profiles in beta-thalassemia patients: a cross-sectional analysis.

Hematology 2019 Dec;24(1):308-317

e Department of Biochemistry, Faculty of Medicine , Northern Border University , Arar , Saudi Arabia.

Objectives: Beta-thalassemia (β-thal) is one of the most common genetic disorders worldwide. Multiple genetic and epigenetic mechanisms could be implicated in the pathogenesis and/or phenotype variations. We sought to explore the serum expression profile of three disease-related long non-coding RNAs (lncRNAs) in a sample of Egyptian β-thal patients with correlation to the patients' clinicolaboratory data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1570616DOI Listing
December 2019
3 Reads
1.189 Impact Factor

Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis.

Hematology 2019 Dec;24(1):318-324

b Department of Clinical Therapeutics , School of Medicine, National and Kapodistrian University of Athens , Athens , Greece.

Introduction: Noggin is an antagonist of bone morphogenetic proteins (BMPs) and has a strong effect on osteogenesis. Osteoporosis is a common complication of transfusion dependent beta-thalassemia (TDT) and denosumab has been recently emerged as a promising therapeutic option. This was a post hoc investigation of serum noggin levels among TDT patients with osteoporosis who participated in a randomized, placebo-control, phase 2b study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1570617DOI Listing
December 2019
4 Reads

Differentially expressed plasma proteins of β-thalassemia/hemoglobin E patients in response to curcuminoids/vitamin E antioxidant cocktails.

Hematology 2019 Dec;24(1):300-307

a Department of Biochemistry, Faculty of Medicine Siriraj Hospital , Mahidol University , Bangkok , Thailand.

Objective: Iron overload and oxidative stress are the major causes of serious complications and mortality in thalassemic patients. Our previous work supports the synergistic effects of antioxidant cocktails (curcuminoids or vitamin E, N-acetylcysteine, and deferiprone) in treatment of β-thalassemia/Hb E patients. This further 2-DE-based proteomic study aimed to identify the plasma proteins that expressed differentially in response to antioxidant cocktails. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1568354DOI Listing
December 2019
3 Reads

TACO and TRALI: biology, risk factors, and prevention strategies.

Authors:
Nareg Roubinian

Hematology Am Soc Hematol Educ Program 2018 11 14;2018(1):585-594. Epub 2018 Dec 14.

Blood Systems Research Institute, San Francisco, CA; Kaiser Permanente Northern California Medical Center and Division of Research, Oakland, CA; and Department of Laboratory Medicine, University of California, San Francisco, CA.

Transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO) are the leading causes of transfusion-related morbidity and mortality. These adverse events are characterized by acute pulmonary edema within 6 hours of a blood transfusion and have historically been difficult to study due to underrecognition and nonspecific diagnostic criteria. However, in the past decade, in vivo models and clinical studies utilizing active surveillance have advanced our understanding of their epidemiology and pathogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.585DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324877PMC
November 2018
1 Read

International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.

Hematology 2019 Dec;24(1):238-246

h Ain Shams University , Cairo , Egypt.

Objective: The study evaluates the long-term deferasirox treatment of adult and pediatric patients with chronic transfusional iron overload in clinical practice.

Methods: In this non-interventional study, patients were observed for up to 3 years from initiation of deferasirox treatment both prospectively and retrospectively for up to 1 year prior to enrollment. The primary end points were the proportion of patients with ≥1 notable increase in serum creatinine (SCr), and ≥1 notable increase in alanine aminotransferase (ALT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2018.1558758DOI Listing
December 2019
4 Reads
1.189 Impact Factor

Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan.

Hematology 2019 Dec;24(1):247-254

k Department of Internal Medicine , Chung Shan Medical University Hospital , Taichung , Taiwan.

Objective: Patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) or other rare anemia require chronic blood transfusions which can lead to iron overload and subsequent excess iron-mediated complications. Intensive iron chelation with deferasirox could remove excess iron and can alleviate these events; however, the long-term safety and efficacy in Chinese population are not clearly characterized. This study examined the long-term efficacy and safety of deferasirox in a real-world setting in Taiwan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2018.1557860DOI Listing
December 2019
9 Reads

Drug-associated thrombocytopenia.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):576-583

Transfusion Medicine, Medical Faculty of Tubingen, University of Tubingen, Tubingen, Germany.

Many drugs have been implicated in drug-induced immune thrombocytopenia (DITP). Patients with DITP develop a drop in platelet count 5 to 10 days after drug administration with an increased risk of hemorrhage. The diagnosis of DITP is often challenging, because most hospitalized patients are taking multiple medications and have comorbidities that can also cause thrombocytopenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.576DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246020PMC
November 2018
7 Reads

How do we diagnose immune thrombocytopenia in 2018?

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):561-567

Michael G. DeGroote School of Medicine, Department of Medicine and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.

In this report, we will review the various clinical and laboratory approaches to diagnosing immune thrombocytopenia (ITP), with a focus on its laboratory diagnosis. We will also summarize the results from a number of laboratories that have applied techniques to detect anti-platelet autoantibodies as diagnostic tests for ITP. Although there is considerable variability in methods among laboratories, there is general agreement that platelet autoantibody testing has a high specificity but low sensitivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.561DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245958PMC
November 2018
22 Reads

Shifting ground and gaps in transfusion support of patients with hematological malignancies.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):553-560

Laboratory Medicine and Pathobiology (Transfusion Medicine) and Medicine (Clinical Hematology), University Health Network/University of Toronto, Toronto, ON, Canada.

The transfusion support of hematological malignancies considers 2 dimensions: the quantity of what we order (in terms of triggers, doses, targets, and intervals), and the special qualities thereof (with respect to depths of matching and appropriate product modifications). Meanwhile, transfusion-related enhancements in the quantity and quality of life may not be dose dependent but rather tempered by unintended patient harms and system strains from overexposure. Evidence and guidelines concur in endorsing clinically noninferior conservative red blood cell (RBC) transfusion care strategies (eg, triggering at hemoglobin <7-8 g/dL and in single-unit doses for stable, nonbleeding inpatients). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.553DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246005PMC
November 2018
5 Reads

Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):539-547

Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

The advent of plasma exchange has dramatically changed the prognosis of acute thrombotic thrombocytopenic purpura (TTP). Recent insights into TTP pathogenesis have led to the development of novel therapies targeting pathogenic anti-ADAMTS13 antibody production, von Willebrand factor (VWF)-platelet interactions, and ADAMTS13 replacement. Retrospective and prospective studies have established the efficacy of rituximab as an adjunct to plasma exchange for patients with acute TTP, either upfront or for refractory disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.539DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246029PMC
November 2018
17 Reads

Clinical and laboratory diagnosis of TTP: an integrated approach.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):530-538

Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Thrombotic thrombocytopenia purpura (TTP) is a rare, life-threatening disease with an incidence of approximately 2 persons per million per year. It is characterized by severe deficiency of the von Willebrand cleaving protease, ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), leading to formation of platelet-rich thrombi in the microvasculature. Prompt initiation of appropriate therapy, particularly plasma exchange, may be life-saving. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.530DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246034PMC
November 2018
15 Reads

Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):482-492

Division of Hematology/Oncology and UPMC Heart, Lung and Blood Vascular Medicine Institute, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Progress in the care of sickle cell disease (SCD) has been hampered by the extreme complexity of the SCD phenotype despite its monogenic inheritance. While epidemiological studies have identified clinical biomarkers of disease severity, with a few exceptions, these have not been routinely incorporated in clinical care algorithms. Furthermore, existing biomarkers have been poorly apt at providing objective parameters to diagnose sickle cell crisis, the hallmark, acute complication of SCD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246014PMC
November 2018
15 Reads

The current state of sickle cell trait: implications for reproductive and genetic counseling.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):474-481

Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD.

Sickle cell trait (SCT) is unique among the carrier states that are identified during newborn screening. Unlike other heterozygous states for rare recessive diseases, SCT is exceedingly prevalent throughout regions of the world, making sickle cell disease one of the most common monogenetic diseases worldwide. Because of this high frequency, reproductive counseling is of paramount importance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.474DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245976PMC
November 2018
3 Reads

A brief, but comprehensive, guide to clonal evolution in aplastic anemia.

Authors:
Daria V Babushok

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):457-466

Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA; and.

Acquired aplastic anemia (AA) is an immune-mediated bone marrow aplasia that is strongly associated with clonal hematopoiesis upon marrow recovery. More than 70% of AA patients develop somatic mutations in their hematopoietic cells. In contrast to other conditions linked to clonal hematopoiesis, such as myelodysplastic syndrome (MDS) or clonal hematopoiesis of indeterminate potential in the elderly, the top alterations in AA are closely related to its immune pathogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.457DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245980PMC
November 2018
13 Reads

Activity of eltrombopag in severe aplastic anemia.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):450-456

Division of Hematology, Hospital A Beneficência Portuguesa, Sao Paulo, Brazil.

Since the approval of horse antithymocyte globulin (ATG) decades ago, there was a long hiatus in therapies with activity in severe aplastic anemia (SAA). This scenario changed in 2014 when eltrombopag, a thrombopoietin receptor agonist, was approved for SAA after an insufficient response to initial immunosuppressive therapy (IST). The basis for this approval was the observation of single-agent activity of eltrombopag in this patient population, where 40% to 50% recovered blood counts at times involving >1 lineage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.450DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245975PMC
November 2018
2 Reads

Anticoagulating patients with high-risk acquired thrombophilias.

Authors:
Leslie Skeith

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):439-449

Division of Hematology and Hematological Malignancies, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Canada; and Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada.

Antiphospholipid syndrome (APS), heparin-induced thrombocytopenia, and paroxysmal nocturnal hemoglobinuria are 3 acquired thrombophilias that carry a high risk of venous and arterial thromboembolism. Management of these conditions has largely included anticoagulation with a vitamin K antagonist after an initial period of a parenteral anticoagulant, for as long as the thrombotic risk is still present. The available evidence for the use of direct oral anticoagulants (DOACs) is limited and primarily consists of case series and cohort studies, which are summarized in this chapter. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.439DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246016PMC
November 2018
4 Reads

Breadth of complications of long-term oral anticoagulant care.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):432-438

Department of Medicine and Surgery, University of Insubria, Varese, Italy.

The majority of patients with venous thromboembolism (VTE) have a considerable long-term risk of recurrence and may require extended duration of anticoagulant treatment after the initial 3 to 6 months. The decision to extend treatment is based not only on the individual risk of recurrence, but should also consider the potential complications associated with anticoagulation, taking into account that anticoagulant drugs are among the drugs most frequently associated with hospital admission due to adverse drug reactions. The most feared complication of oral anticoagulants is bleeding, which in some cases may be fatal or may affect critical organs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245998PMC
November 2018
2 Reads

Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):426-431

Ottawa Blood Disease Centre, Ottawa Hospital, Ottawa, Ontario, Canada.

After an initial 3 to 6 months of anticoagulation for venous thromboembolism (VTE), clinicians and patients face an important question: "Do we stop anticoagulants or continue them indefinitely?" The decision is easy in some scenarios (eg, stop in VTE provoked by major surgery). In most scenarios, which are faced on a day-to-day basis in routine practice, it is a challenging decision because of uncertainty in estimates in the long-term risks (principally major bleeding) and benefits (reducing recurrent VTE) and the tight trade-offs between them. Once the decision is made to continue, the next question to tackle is "Which anticoagulant?" Here again, it is a difficult decision because of the uncertainty with regard to estimates of efficacy and the safety of anticoagulant options and the tight trade-offs between choices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.426DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246028PMC
November 2018
2 Reads

Management of thrombosis in children and neonates: practical use of anticoagulants in children.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):399-404

Department of Clinical Haematology, Royal Children's Hospital, Haematology Research Murdoch Children's Research Institute, School of Nursing, University of Melbourne, Melbourne, VIC, Australia.

Venous thrombosis (VTE) in children and neonates presents numerous management challenges. Although increasing in frequency, VTE in children and neonates is still uncommon compared with adults. The epidemiology of VTE is vastly different in neonates vs children vs adolescents vs adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.399DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245972PMC
November 2018
7 Reads

Evaluation and management of heavy menstrual bleeding in adolescents: the role of the hematologist.

Authors:
Sarah H O'Brien

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):390-398

Division of Pediatric Hematology/Oncology, Nationwide Children's Hospital, The Ohio State University, Columbus, OH; and.

Heavy menstrual bleeding (HMB) is frequently reported by adolescents. The role of the hematologist is threefold in evaluating such patients: (1) perform a clinical and laboratory evaluation for an underlying bleeding disorder on the basis of the degree of clinical suspicion, (2) identify and manage any concomitant iron deficiency, and (3) provide input to the referring provider regarding the management of HMB, particularly for patients with identified hemostatic defects. Several clues in the menstrual history should raise suspicion for an underlying bleeding disorder, such as menses lasting >7 days, menstrual flow which soaks >5 sanitary products per day or requires product change during the night, passage of large blood clots, or failure to respond to conventional therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.390DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246024PMC
November 2018
5 Reads

Autoimmune hemolytic anemia.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):382-389

Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom.

The diagnosis of autoimmune hemolytic anemia (AIHA) can be made with a stepwise approach that aims to identify laboratory and clinical evidence of hemolysis and then determine the immune nature of hemolysis with the direct anti-globulin test. Once alternative causes for these findings have been excluded, AIHA is established, and the clinician must search for secondary causes, as well as identify the type of AIHA. Rituximab is now the preferred second-line treatment for primary warm AIHA and first-line treatment for primary cold agglutinin disease (CAD), either as monotherapy or combined with bendamustine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.382DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246027PMC
November 2018
17 Reads

Inherited hemolytic anemia: a possessive beginner's guide.

Authors:
Narla Mohandas

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):377-381

New York Blood Center, New York, NY.

Significant advances have been made in diagnosis and clinical management of inherited red cell membrane disorders that result in hemolytic anemia. Membrane structural defects lead to hereditary spherocytosis (HS) and hereditary elliptocytosis (HE), whereas altered membrane transport function accounts for hereditary xerocytosis (HX) and hereditary overhydrated stomatocytosis (OHS). The degrees of membrane loss and resultant increases in cell sphericity determine the severity of anemia in HS and HE, and splenectomy leads to amelioration of anemia by increasing the circulatory red cell life span. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.377DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245988PMC
November 2018
4 Reads

Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):371-376

Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

Atypical hemolytic uremic syndrome (aHUS); hemolysis, elevated liver function tests, and low platelets syndrome; and transplant-associated thrombotic microangiopathy are related conditions, in that many patients harbor germline heterozygous mutations in genes that regulate the alternative pathway of complement (APC). Penetrance is variable because development of clinically significant disease appears to require supervention of a process such as inflammation. Complement activation on the endothelial surfaces leads to endothelial damage, platelet consumption, microthrombi, and a mechanical hemolytic anemia with schistocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.371DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245985PMC
November 2018
3 Reads

Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy.

Authors:
John Porter

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):361-370

University College London, London, United Kingdom.

Transfusion combined with chelation therapy for severe β thalassemia syndromes (transfusion-dependent thalassemia [TDT]) has been successful in extending life expectancy, decreasing comorbidities and improving quality of life. However, this puts lifelong demands not only on the patients but also on the health care systems that are tasked with delivering long-term treatment and comprehensive support. Prevention programs and curative approaches are therefore an important part of overall strategy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.361DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245990PMC
November 2018
2 Reads

Role of the anticoagulant monitoring service in 2018: beyond warfarin.

Authors:
Nathan P Clark

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):348-352

Kaiser Permanente Colorado, Aurora, CO; and Department of Clinical Pharmacy, Colorado University Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO.

The direct oral anticoagulants (DOACs) have a wide therapeutic index, few drug interaction, no dietary interactions and do not require dose adjustment according to the results of routine coagulation testing. Despite these advantages over warfarin, the DOACs remain high risk medications. There is evidence that non-adherence, off-label dosing and inadequate care transitions during DOAC therapy increase the risk of bleeding and thromboembolic complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246023PMC
November 2018
2 Reads

Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):318-325

Division of Translational Medicine & Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Castleman disease (CD) describes a heterogeneous group of hematologic disorders that share characteristic lymph node histopathology. Patients of all ages present with either a solitary enlarged lymph node (unicentric CD) or multicentric lymphadenopathy (MCD) with systemic inflammation, cytopenias, and life-threatening multiple organ dysfunction resulting from a cytokine storm often driven by interleukin 6 (IL-6). Uncontrolled human herpesvirus-8 (HHV-8) infection causes approximately 50% of MCD cases, whereas the etiology is unknown in the remaining HHV-8-negative/idiopathic MCD cases (iMCD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245974PMC
November 2018
2 Reads

JMML genomics and decisions.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):307-312

Department of Pediatrics and Adolescent Medicine, University Children's Hospital, University of Freiburg, Freiburg, Germany.

Juvenile myelomonocytic leukemia (JMML) is a unique clonal hematopoietic disorder of early childhood characterized by hyperactivation of the RAS signal transduction pathway. Approximately 90% of patients harbor molecular alteration in 1 of 5 genes (), which define genetically and clinically distinct JMML subtypes. Three subtypes, , and -mutated JMML, are characterized by heterozygous somatic gain-of-function mutations in non syndromic children, while two subtypes, JMML in neurofibromatosis type 1 and in JMML in children with CBL syndrome, are characterized by germ line RAS disease and acquired biallelic inactivation of the respective tumor suppressor genes in hematopoietic cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.307DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245977PMC
November 2018
4 Reads

Ethical conundrums in pediatric genomics.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):301-306

Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic Children's Hospital, Cleveland, OH.

Recent genomic discoveries have improved our understanding of many hematologic diseases and led to novel therapeutic options for many patients. The rapid decrease in the cost of genomic testing has enabled widespread use of clinical genomic testing. However, these advances are accompanied by concomitant challenging ethical concerns. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.301DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245967PMC
November 2018
1 Read

Using genomics to define pediatric blood cancers and inform practice.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):286-300

Department of Pediatrics, Benioff Children's Hospital and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.

Over the past decade, there has been exponential growth in the number of genome sequencing studies performed across a spectrum of human diseases as sequencing technologies and analytic pipelines improve and costs decline. Pediatric hematologic malignancies have been no exception, with a multitude of next generation sequencing studies conducted on large cohorts of patients in recent years. These efforts have defined the mutational landscape of a number of leukemia subtypes and also identified germ-line genetic variants biologically and clinically relevant to pediatric leukemias. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.286DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245969PMC
November 2018
2 Reads

The MDS genomics-prognosis symbiosis.

Authors:
Aziz Nazha

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):270-276

Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

Myelodysplastic syndromes (MDS) are clonal disorders characterized by the accumulation of complex genomic abnormalities that define disease phenotype, prognosis, and the risk of transformation to acute myeloid leukemia. The clinical manifestations and overall outcomes of MDS are very heterogeneous with an overall survival that can be measured in years for some patients to a few months for others. Prognostic scoring systems are important staging tools that aid physicians in their treatment recommendations and decision-making and can help patients understand their disease trajectory and expectations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246025PMC
November 2018
8 Reads

Clinical consequences of clonal hematopoiesis of indeterminate potential.

Authors:
David P Steensma

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):264-269

Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

Clonally restricted hematopoiesis is a common aging-associated biological state that predisposes to subsequent development of a hematological malignancy or cardiovascular death. Clonal expansion driven by leukemia-associated somatic mutations, such as , , or , is best characterized, but oligoclonality can also emerge without recognized leukemia-driver mutations, perhaps as a result of stochastic neutral drift. Murine models provide compelling evidence that a major mechanism of increased cardiovascular mortality in the context of clonal hematopoiesis is accelerated atherogenesis driven by inflammasome-mediated endothelial injury, resulting from proinflammatory interactions between endothelium and macrophages derived from circulating clonal monocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.264DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245996PMC
November 2018
16 Reads

Relapsed CLL: sequencing, combinations, and novel agents.

Authors:
Jennifer R Brown

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):248-255

CLL Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

Although the therapy of chronic lymphocytic leukemia (CLL) has changed rapidly over the last 5 years, the key considerations in selecting a therapy for a previously treated patient with CLL continue to include the nature of the prior therapy and the duration of prior remission to that therapy, the prognostic features of the disease, and the health and comorbidities of the patient in question. For patients treated initially with chemoimmunotherapy, randomized trials have demonstrated the benefit of targeted therapy. Retrospective data suggest that ibrutinib is preferred as a first kinase inhibitor, whereas recent data with venetoclax and rituximab may challenge the choice of ibrutinib as a first novel agent in the relapsed setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.248DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245984PMC
November 2018
14 Reads

Selecting Frontline Therapy for CLL in 2018.

Authors:
Nitin Jain

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):242-247

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

The treatment landscape of chronic lymphocytic leukemia (CLL) has changed dramatically in the last few years. The role of chemoimmunotherapy has declined significantly for patients with CLL. Fludarabine, cyclophosphamide, rituximab chemotherapy remains the standard frontline therapy for young fit patients with CLL, especially if mutated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.242DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245995PMC
November 2018
13 Reads

Biology-driven developments in the therapy of acute graft-versus-host disease.

Authors:
Robert Zeiser

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):236-241

Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Freiburg University Medical Center, Freiburg, Germany.

Allogeneic hematopoietic cell transplantation is a potentially curative treatment of different hematological malignancies. A major life-threatening complication is acute graft-versus-host disease (GVHD), in particular when the disease becomes steroid refractory. Based on the detection of pathogenic cytokines, chemokines, and T-cell subsets in individuals developing GVHD or experimental GVHD models, different therapeutic strategies have been developed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.236DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245989PMC
November 2018
1 Read

Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):228-235

Blood and Marrow Transplant Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

Allogeneic hematopoietic cell transplantation is a potentially curative therapy for many malignant and nonmalignant hematologic diseases. Graft-versus-host disease (GVHD) is a common complication after transplantation and remains a major cause of morbidity and mortality, limiting the success of a potentially curative transplant. This paper reviews the current and emerging strategies in GVHD prevention and treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.228DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246030PMC
November 2018
15 Reads

GVHD: biology matters.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):221-227

The Tisch Cancer Institute and Division of Hematology/Medical Oncology, The Icahn School of Medicine at Mount Sinai Hospital, New York, NY.

Acute graft-versus-host disease (GVHD) targets the crypts in the gastrointestinal (GI) tract that are responsible for the self-renewal of the intestinal mucosa. Recent advances in the identification and culture of intestinal stem cells have improved our understanding of the interactions between the microbiome and the immune system (both innate and adaptive) that are key to the pathophysiology of GVHD. The identification of serum biomarkers that best predict long-term GVHD outcomes derive from the GI tract and have focused attention on cellular elements that act as shields against GVHD as well as its targets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.221DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245966PMC
November 2018
4 Reads

Where does PD-1 blockade fit in HL therapy?

Authors:
Alex F Herrera

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):213-220

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.

Genetic alterations of the / locus on chromosome 9p24.1 are a defining biological feature of classical Hodgkin lymphoma (HL). The resulting programmed death-ligand 1 (PD-L1) expression on Hodgkin Reed-Sternberg cells as well as the PD-L1 expressed in the HL microenvironment result in an ineffective host antitumor immune response and make HL a ripe target for programmed cell death-1 (PD-1) blockade. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246012PMC
November 2018
23 Reads